InflammaGen™ Therapeutics to Commence Phase 2 Pilot Study of InflammaGen Shok-Pak Bradenton Herald By InflammaGen Therapeutics SAN DIEGO, March 12, 2012 — /PRNewswire/ -- InflammaGen™ Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today ... InflammaGen(TM) Therapeutics to Commence Phase 2 Pilot Study of InflammaGen ... A lifetime of research may be leading to a life-saving treatment for shock San Diego's InflammaGen Advances Therapy to Mitigate Effects of Shock |
